Published in Ultrasound Med Biol on January 01, 1983
Esophageal variceal pressure influence on the effect of ligation. World J Gastroenterol (2015) 0.75
Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet (1999) 5.27
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene (2008) 4.11
Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall Med (2008) 3.49
Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation (1998) 2.75
Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology (1995) 2.63
Mediterranean spotted fever: clinical, laboratory and epidemiological features of 199 cases. Am J Trop Med Hyg (1986) 2.42
Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther (2009) 2.41
The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology (1990) 2.32
Measurement of gastric emptying time by real-time ultrasonography. Gastroenterology (1985) 2.32
Endoscopic demonstration of loss of duodenal folds in the diagnosis of celiac disease. N Engl J Med (1988) 2.27
Screening test for coeliac disease. Lancet (1997) 2.23
Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet (1998) 2.15
Detection of malabsorption of low doses of carbohydrate: accuracy of various breath H2 criteria. Gastroenterology (1993) 2.15
Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet (2000) 2.13
Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Aliment Pharmacol Ther (2011) 2.12
Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer (1995) 2.11
Atrophic gastritis as a cause of hyperhomocysteinaemia. Aliment Pharmacol Ther (2004) 2.09
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev (2010) 2.09
Hydrogen peroxide-related colitis (previously known as "pseudolipomatosis"): a series of cases occurring in an epidemic pattern. Endoscopy (2007) 2.07
Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant (2008) 2.06
The role of gastroenterologists and digestive surgeons in ultrasonography. Ital J Gastroenterol (1992) 2.04
Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer (1992) 2.01
Atypical sarcoidosis: case reports and review of the literature. Eur Rev Med Pharmacol Sci (2009) 1.98
What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol (1997) 1.98
Real-time detection of Helicobacter Pylori infection and atrophic gastritis: comparison between conventional methods and a novel device for gastric juice analysis during endoscopy. Endoscopy (2005) 1.97
Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology (2000) 1.94
Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther (2003) 1.88
The structure and antigenicity of a type C foot-and-mouth disease virus. Structure (1994) 1.82
Prevalence of spontaneous hepatofugal portal flow in liver cirrhosis. Clinical and endoscopic correlation in 228 patients. Gastroenterology (1991) 1.82
Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol (1997) 1.81
Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2005) 1.78
Protective immune response against foot-and-mouth disease. J Virol (1992) 1.77
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther (2006) 1.76
Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther (2002) 1.73
Effect of meal on portal hemodynamics in healthy humans and in patients with chronic liver disease. Hepatology (1989) 1.70
Guidelines for the use of contrast agents in ultrasound. January 2004. Ultraschall Med (2004) 1.68
Helicobacter pylori reinfection and rapid relapse of low-grade B-cell gastric lymphoma. Lancet (1995) 1.68
Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography. Dig Liver Dis (2008) 1.65
Body composition changes induced by chronic ethanol abuse: evaluation by dual energy X-ray absorptiometry. Am J Gastroenterol (2000) 1.63
Oral disodium cromoglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type. Am J Gastroenterol (1992) 1.62
Autoimmune enteropathy and villous atrophy in adults. Lancet (1997) 1.62
Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci (1998) 1.61
Reversal of fundic atrophy after eradication of Helicobacter pylori. Am J Gastroenterol (1998) 1.61
Prevalence and early diagnosis of coeliac disease in autoimmune thyroid disorders. Ital J Gastroenterol Hepatol (1999) 1.60
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther (2003) 1.59
Bone mass and metabolism in patients with celiac disease. Gastroenterology (1995) 1.59
Endoscopic markers in adult coeliac disease. Dig Liver Dis (2002) 1.58
Serological screening of coeliac disease: choosing the optimal procedure according to various prevalence values. Gut (1994) 1.57
A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C. J Gen Virol (1990) 1.57
Value of splanchnic Doppler ultrasound in the diagnosis of portal hypertension. Ultrasound Med Biol (2001) 1.56
Methodology of the H2 breath test. II. Importance of the test duration in the diagnosis of carbohydrate malabsorption. Ital J Gastroenterol (1990) 1.55
Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2005) 1.54
Superior mesenteric artery impedance in chronic liver diseases: relationship with disease severity and portal circulation. Am J Gastroenterol (1998) 1.54
Howell-Jolly body counting as a measure of splenic function. A reassessment. Clin Lab Haematol (1990) 1.54
Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: a study of 40 cases. Br J Rheumatol (1998) 1.54
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther (2001) 1.52
Ultrasonography in the diagnosis of portal hypertension: diminished response of portal vessels to respiration. Radiology (1982) 1.52
Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol (1997) 1.52
Ciprofloxacin therapy for Mediterranean spotted fever. Antimicrob Agents Chemother (1986) 1.51
Epithelial-cell apoptosis and proliferation in Helicobacter pylori-related chronic gastritis. Ital J Gastroenterol Hepatol (1998) 1.50
Investigation of exocrine pancreatic function by continuous infusion of caerulein and secretin in normal subjects and in chronic pancreatitis. Digestion (1976) 1.47
Anticholinergic syndrome due to 'Devil's herb': when risks come from the ancient time. Int J Clin Pract (2006) 1.45
Clinical and manometric effects of nifedipine in patients with esophageal achalasia. Gastroenterology (1981) 1.45
Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut (2004) 1.44
A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology (1989) 1.43
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital J Gastroenterol Hepatol (1999) 1.43
Clinical nutrition practice in Italian Gastroenterology Units. Dig Liver Dis (2001) 1.42
Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig Liver Dis (2003) 1.42
Ageing affects anoxia/reoxygenation injury in rat hepatocytes. Scand J Gastroenterol (1998) 1.42
No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol (1995) 1.42
Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study. Ital J Gastroenterol Hepatol (1999) 1.41
Doppler ultrasound evaluation of acute effects of cigarette smoking on portal blood flow in man. J Gastroenterol Hepatol (1996) 1.40
Effects of Lactobacillus GG on genes expression pattern in small bowel mucosa. Dig Liver Dis (2005) 1.39
Effect of a vegetable-protein-rich polymeric diet treatment on body composition and energy metabolism in inactive Crohn's disease. Eur J Gastroenterol Hepatol (2000) 1.39
Subclinical coeliac disease is a frequent cause of iron-deficiency anaemia. Scand J Gastroenterol (1995) 1.39
[Whipple's disease: progress in the diagnosis and review of the literature]. Minerva Med (2002) 1.38
Acquired gastric mucosa-associated lymphoid tissue (MALT): a review with special emphasis on association with extragastric diseases and management problems of gastric MALT. J Clin Gastroenterol (1999) 1.38
Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. Alcohol Clin Exp Res (2000) 1.38
Bacteroides thetaiotaomicron in the gut: molecular aspects of their interaction. Dig Liver Dis (2007) 1.36
DR and non-DR Ia allotypes are associated with susceptibility to coeliac disease. Gut (1985) 1.35
Assessment of portal hypertension by endoscopic ultrasonography. Gastrointest Endosc (1990) 1.34
Gastrointestinal amyloidosis: a case of chronic diarrhoea. Eur Rev Med Pharmacol Sci (2009) 1.31
Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency. Diabetes (1999) 1.31
Quantitative assessment of the mucosal architecture of jejunal biopsy specimens: a comparison between linear measurement, stereology, and computer aided microscopy. J Clin Pathol (1985) 1.30
Incidence, clinical observations and risk factors in the severe form of Mediterranean spotted fever among patients admitted to hospital in Marseilles 1983-1984. J Infect (1986) 1.30
Anisakis infestation: a case of acute abdomen mimicking Crohn's disease and eosinophilic gastroenteritis. Dig Liver Dis (2005) 1.27
Molecular analysis of encephalomyocarditis viruses isolated from pigs and rodents in Italy. Virus Res (1998) 1.27
Insulin resistance directly correlates with increased saturated fatty acids in skeletal muscle triglycerides. Metabolism (2000) 1.27
The non-structural polyprotein 3ABC of foot-and-mouth disease virus as a diagnostic antigen in ELISA to differentiate infected from vaccinated cattle. Arch Virol (1997) 1.27
Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study. The European Helicobacter pylori HpSA Study Group. Am J Gastroenterol (2000) 1.26
Prevalence and clinical presentation of subclinical/silent celiac disease in adults: an analysis on a 12-year observation. Hepatogastroenterology (2001) 1.25
A further step in the evolution of rabbit hemorrhagic disease virus: the appearance of the first consistent antigenic variant. Virus Res (1998) 1.25
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther (2000) 1.24
Immune protection against foot-and-mouth disease virus studied using virus-neutralizing and non-neutralizing concentrations of monoclonal antibodies. Immunology (1986) 1.24